Navigation Links
Women Using Compounded 'Bioidentical' Hormones Miss the Full Story About These Drugs
Date:12/31/2008

MONTVALE, N.J., Dec. 31 /PRNewswire/ -- Women in, or past, menopause who use specially compounded "bioidentical" hormones to treat menopause-related symptoms, such as hot flushes, often don't get adequate information from compounding pharmacists about the drugs' risks and realistic potential for benefit. That's one of the concerns about these medications addressed by menopause expert JoAnn V. Pinkerton, MD, in "'Bioidentical' hormones: What you (and your patient) need to know," in the January issue of OBG Management.

So-called bioidentical hormones are chemically similar to hormones released by the body, including those produced in the ovaries -- estrone, estradiol, estriol, progesterone, testosterone, and dehydroepiandrosterone, to name some.

"The FDA has approved many prescription products that contain 'bioidentical' hormones," says Pinkerton, "but 'bioidentical' is often used to refer to custom-compounded hormones. The major difference between FDA-approved prescription bioidentical hormone products and custom-compounded products is that only the former are regulated by the FDA and tested for purity, potency, efficacy, and safety."

"That means it's up to physicians who prescribe compounded hormones to educate their patients -- about potential risks and benefits, absence of FDA oversight, purity and potency concerns, and lack of peer-reviewed data on efficacy and safety," Pinkerton says.

"Practitioners need to recognize that women who ask for these hormones may be vulnerable -- because of anxiety and depression that often accompany menopausal symptoms -- to unsubstantiated claims or recommendations of self-proclaimed experts."

"Compounded hormones aren't safer, or more effective, than traditional FDA-approved hormone therapies," Pinkerton emphasizes. "No data support individualized, personalized therapy based on testing hormone levels in saliva. And compounded bioidentical hormones don't prevent cancer; they probably have the same potential to cause cancer, and present the same other health risks, as FDA-approved hormones."

Bioidentical hormones are one of the biggest products of the multibillion-dollar US pharmaceutical compounding industry, observes Bruce Patsner, MD, JD, who contributed to the OBG Management article. Patsner, an expert on pharmacy compounding of prescription hormone therapy, served as senior medical officer at the FDA and is now Research Professor of Law at the University of Houston Law Center.

JoAnn V. Pinkerton, MD, is Professor and Vice Chair of Obstetrics and Gynecology at the University of Virginia Health System in Charlottesville, where she directs The Women's Place Midlife Health Center. She is a member of the Board of Editors of OBG Management, a review publication for ObGyns (www.obgmanagement.com).


'/>"/>
SOURCE Dowden Health Media
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
2. Work-Family Conflict Dogs Air Force Women After Deployment
3. Work-Family Conflict Dogs Air Force Women After Deployment
4. Antioxidant Supplements May Raise Womens Skin Cancer Risk
5. Early Weight Loss in Women Linked to Dementia
6. For Health Info, Women Often Turn to the Web
7. Smoking increases risks for head and neck cancers for men and women
8. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
9. Passive smoking increases sleep disturbance among pregnant women
10. Trial to Test Gene Therapy for Angina in Women
11. Exercise and yoga improves quality of life in women with early-stage breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... Angeles, California (PRWEB) , ... May 26, 2017 , ... ... senior citizens who visit a doctor for colds or respiratory issues that are not ... that excessive time pressure on doctors may be largely responsible for the problem both ...
(Date:5/27/2017)... ... , ... Most us are familiar with the sound of occasional popping joints ... Initiative shows that certain people who experience consistent joint popping, grating and grinding ... the opportunity to treat patients before the problem becomes pronounced, potentially hedging off more ...
(Date:5/26/2017)... ... May 26, 2017 , ... The ... educational seminar to focus on current legislative activity and the latest regulatory concerns ... 1 p.m. Sunday, Sept. 10, and will continue through Monday, Sept. 11, at ...
(Date:5/26/2017)... ... 2017 , ... Boar’s Head Brand®, one of the nation’s ... entertaining that are sure to satisfy your guests’ flavor cravings, while adding delicious ... featured in these refreshingly balanced recipes are packed with flavor, creating the perfect ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Yisrayl Hawkins, ... new publication this week that is focusing on the Peace Agreements being discussed by ... Middle East sprint in a race to try to speed up peace talks in ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... May 22, 2017  As the specialty pharmacy ... continue to make the revolutionary shift from volume-based ... for ensuring positive patient outcomes and shaping the ... shifting focus away from clinical trials and toward ... long-term specialty drug therapy utilization in precise patient ...
(Date:5/18/2017)... 2017  Bayer announced today that the latest research ... at the 53 rd Annual Meeting of the ... 2-6 in Chicago . ... colorectal, liver and thyroid cancers, as well as lymphomas, ... CHRONOS-1 trial of copanlisib in patients with relapsed or ...
(Date:5/15/2017)... PHILADELPHIA , May 15, 2017 Enterin Inc., ... and developing novel compounds to treat Parkinson,s disease ... The study is a Phase 1/2a randomized, controlled, multicenter study ... sites. It will enroll 50 patients over a 9-to-12-month period. ... doses in 10 patients with PD. Participating sites include ...
Breaking Medicine Technology: